Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + dexamethasone for relapsed/refractory multiple myeloma
ChiCTR2500097934Phase 4Not yet recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Mar 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pyrotinib and dexamethasone in multiple myeloma (MM), sponsored by The First Hospital of Fujian Medical University. Primary endpoint: Objective response rate. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
pyrotinibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2500097934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097934.